Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers

Journal of Biomedical Nanotechnology

Volumn 3, Issue 4, 2007, Pages 367-376

  Corbin, Ian R ^a,b,c   Chen, Juan ^a,b,c   Cao, Weiguo ^d   Li, Hui ^c   Lund Katz, Sissel ^c   Zheng, Gang ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SHANGHAI UNIVERSITY   (China)

Author keywords

Cancer; Lipoprotein; Nanoparticle; Near infrared fluorescence imaging; Reticular endothelial system

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; APOLIPOPROTEIN A1; FOLATE RECEPTOR; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; LIGAND; MOLECULAR SCAFFOLD; NANOCARRIER; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CANCER DIAGNOSIS; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENGINEERING; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; SYNTHESIS; TUMOR CELL;

EID: 45849128001     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.053     Document Type: Article

References (35)

1. D. F. Emerich and C. G. Thanos, The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 23, 171 (2006).
2. E. S. Kawasaki and A. Player, Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine: Nanotechnology, Biology, and Medicine 1, 101 (2005).
3. K. E. Kagan, H. Bayir, and A. A. Shvedova, Nanomedicine and nanotoxicology: Two sides of the same coin. Nanomedicine: Nanotechnology, Biology, and Medicine 1, 313 (2005).
4. G. Poste, C. Bucana, A. Raz, P. Bugelski, R. Kirsh, and I. J. Fidler, Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42, 1412 (1982).
5. D. Papahadjopoulos, T. M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S. K. Huang, K. D. Lee, M. C. Woodle, D. D. Lasic, C. Redemann, and F. J. Martin, Sterically stabilized liposomes: Improvements in pharmacokineticsand antitumor therapeutic efficacy. Proceedings of the National Academy of Sciences of the United States of America 88, 11460 (1991).
6. D. Bhadra, S. Bhadra, P. Jain, and N. K. Jain, Pegnology: A review of PEG-ylated systems. Die Pharmazie 57, 5 (2002).
7. H. Saito, P. Dhanasekaran, D. Nguyen, P. Holvoet, S. Lund-Katz, and M. C. Phillips, Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J. Biol. Chem. 278, 23227 (2003).
8. R. C. Pittman, C. K. Glass, D. Atkinson, and D. M. Small, Synthetic high density lipoprotein particles. Application to studies of the apoprotein specificity for selective uptake of cholesterol esters. J. Biol. Chem. 262, 2435 (1987).
9. G. Zheng, J. Chen, H. Li, and J. D. Glickson, Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proceedings of the National Academy of Sciences of the United States of America 102, 17757 (2005).
10. S. Acton, A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518 (1996).
11. J. J. Turek, C. P. Leamon, and P. S. Low, Endocytosis of folate protein conjugates: Ultrastructural localization in KB cells. J. Cell. Sci. 106, 423 (1993).
12. J. F. Ross, P. K. Chaudhuri, and M. Ratnam, Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73, 2432 (1994).
13. E. T. Dams, P. Laverman, W. J. Oyen, G. Storm, G. L. Scherphof, J. W. van Der Meer, F. H. Corstens, and O. C. Boerman, Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 292, 1071 (2000).
14. M. K. Bijsterbosch and T. J. Van Berkel, Native and modified lipoproteins as drug delivery systems. Adv. Drug Deliv. Rev. 5, 231 (1990).
15. M. K. Bijsterbosch and T. J. Van Berkel, Lactosylated high density lipoprotein: A potential carrier for the site-specific delivery of drugs to parenchymal liver cells. Mol. Pharmacol. 41, 404 (1992).
16. M. K. Bijsterbosch, C. Ying, R. L. de Vrueh, E. de Clercq, E. A. Biessen, J. Neyts, and T. J. van Berkel, Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. Mol. Pharmacol. 60, 521 (2001).
17. S. M. Moerlein, A. Daugherty, B. E. Sobel, and M. J. Welch, Metabolic imaging with gallium-68- and indium-112-labeled low-density lipoprotein. J. Nucl. Med. 32, 300 (1991).
18. J. L. Goldstein, Y. K. Ho, S. K. Basu, and M. S. Brown, Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proceedings of the National Academy of Sciences of the United States of America 76, 333 (1979).
19. S. T. Thuahnai, S. Lund-Katz, P. Dhanasekaran, M. de la Llera-Moya, M. A. Connelly, D. L. Williams, G. H. Rothblat, and M. C. Phillips, Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J. Biol. Chem. 279, 12448 (2004).
20. F. Jasanada, P. Urizzi, J. P. Souchard, F. Le Gaillard, G. Favre, and F. Nepveu, Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): Evaluation as a potential radiopharmaceutical for tumor localization. Bioconjugate Chem. 7, 72 (1996).
21. A. Kader and A. Pater, Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Release 80, 29 (2002).
22. A. G. Lacko, M. Nair, S. Paranjape, S. Johnso, and W. J. McConathy, High density lipoprotein complexes as delivery vehicles for anti-cancer drugs. Anticancer Res. 22, 2045 (2002).
23. J. C. Frias, Y. Ma, K. J. Williams, Z. A. Fayad, and E. A. Fisher, Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6, 2220 (2006).
24. J. C. Frias, K. J. Williams, E. A. Fisher, and Z. A. Fayad, Recombinant HDL-like nanoparticles: A specific contrast agent for MRI of atherosclerotic plaques. J. Amer Chem. Soc. 126, 16316 (2004).
25. M. N. Oda, P. L. Hargreaves, J. A. Beckstead, K. A. Redmond, R. van Antwerpen, and R. O. Ryan, Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J. Lipid Res. 47, 260 (2006).
26. B. Lou, X. L. Liao, M. P. Wu, P. F. Cheng, C. Y. Yin, and Z. Fei, High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J. Gastroenterol. 11, 954 (2005).
27. N. H. Fidge, High density lipoprotein receptors, binding proteins, and ligands. J. Lipid Res. 40, 187 (1999).
28. X. Gu, B. Trigatti, S. Xu, S. Acton, J. Babitt, and M. Krieger, The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J. Biol. Chem. 273, 26338 (1998).
29. O. C. Farokhzad, J. M. Karp, and R. Langer, Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opinion on Drug Delivery 3, 311 (2006).
30. T. I. Samoylova, N. E. Morrison, L. P. Globa, and N. R. Cox, Peptide phage display: Opportunities for development of personalized anti-cancer strategies. Anti-Cancer Agents in Medicinal Chemistry 6, 9 ( 2006).
31. M. K. Bijsterbosch, H. van de Bilt, and T. J. van Berkel, Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem. Pharmacol. 52, 113 (1996).
32. S. D. Weitman, R. H. Lark, L. R. Coney, D. W. Fort, V. Frasca, V. R. Zurawski, Jr., and B. A. Kamen, Distribution of folate recptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52, 396 (1992).
33. M. Krieger, Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem. 68, 523 (1999).
34. J. L. Goldstein, M. S. Brown, R. G. Anderson, D. W. Russell, and W. J. Schneider, Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol. 1, 1 (1985).
35. H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. Jain, and D. M. McDonald, Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363 (2000).